Meningitis Biomarker Detection via Sequential Proteomic Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for meningitis are inadequate in distinguishing between bacterial and viral meningitis, particularly in differentiating between pneumococcal and meningococcal forms, leading to delayed and inappropriate treatment, increased morbidity, and high treatment costs.
Innovation Solution
A qualitative predictive method based on the combined detection and sequential analysis of specific biomarkers, including apolipoprotein A-I, C-reactive protein, complement C-3 fraction, and kininogen, present in cerebrospinal fluid, to differentiate between viral and bacterial meningitis and determine the etiology of bacterial meningitis as pneumococcal or meningococcal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for meningitis, then treatment can be provided, but accurate differentiation between bacterial and viral meningitis cannot be achieved
Solution Approach 1:
The diagnostic method segments the detection process into multiple sequential stages: first detecting apolipoprotein A-I to identify all meningitis cases, then detecting C-reactive protein and complement C-3 to differentiate bacterial from viral etiology, and finally detecting kininogen to distinguish pneumococcal from meningococcal bacterial meningitis. This segmented approach systematically recovers etiological information that would otherwise be lost.
Solution Approach 2:
The invention adds a new dimension to meningitis diagnosis by introducing a multi-marker proteomic profile approach. Instead of relying on single traditional markers, the method evaluates multiple proteins (apolipoprotein A-I, C-reactive protein, complement C-3, kininogen) across different diagnostic dimensions, enabling precise differentiation between various meningitis etiologies that were previously indistinguishable.
2Reliability
If broad-spectrum antibiotics are administered to all meningitis patients, then potential bacterial infections can be treated, but unnecessary antibiotic exposure increases side effects and costs
Solution Approach 1:
The diagnostic method performs preliminary etiological classification before treatment initiation by detecting specific protein markers. This preliminary action identifies which patients truly have bacterial meningitis and require antibiotics, versus those with viral meningitis who would be harmed by unnecessary antibiotic exposure, thereby eliminating the need for empiric broad-spectrum coverage in all cases.
Solution Approach 2:
The method implements feedback by using detected biomarker profiles to guide treatment decisions. The presence or absence of specific proteins (C-reactive protein, complement C-3, kininogen) provides feedback on etiology, enabling clinicians to adjust antibiotic therapy accordingly - administering antibiotics only when bacterial etiology is confirmed, thus avoiding harmful side effects in viral cases.
3Productivity
If traditional meningitis diagnostic methods are used, then general diagnosis can be made, but specific etiology identification is delayed
Solution Approach 1:
The invention merges multiple diagnostic functions into a single integrated proteomic profiling method. By simultaneously evaluating multiple biomarkers (apolipoprotein A-I, C-reactive protein, complement C-3, kininogen) in one assay system, the method achieves both rapid diagnosis and precise etiological identification, resolving the contradiction between speed and precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate and timely diagnosis of meningitis, reducing hospitalization time, treatment costs, and the risk of antibiotic side effects by distinguishing between viral and bacterial meningitis and identifying the specific bacterial cause, thereby guiding appropriate therapeutic approaches.
Implementation Method 1
The instant invention further provides a meningitis differential diagnostic method based on the application of the predictive method and also provides the possibility of incorporating the method of the instant invention into a diagnostic kit containing ligands to biomarker proteins such as antibodies or aptamers
Data Source
AI summary
The instant invention relates to a qualitative predictive method, to a method, use and kit applied to the early differential diagnosis of the most prevalent forms of bacterial and viral meningitis, enabling to detect and distinguish the different forms of meningitis. The invention uses a qualitative predictive method based on combined detection and sequential analysis of the presence/absence of at least three out of four specific biomarkers.